Vimarsana
Biggest News Aggregation in the World

Page 25 - Benzinga Pro News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Benzinga Pro. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Benzinga Pro Today - Breaking & Trending Today

Unpacking the Latest Options Trading Trends in Abercrombie & Fitch - Abercrombie & Fitch (NYSE:ANF) - Vimarsana News

Unpacking the Latest Options Trading Trends in Abercrombie & Fitch - Abercrombie & Fitch (NYSE:ANF)

Pineapple Energy Stock Soars: What's Going On? - Pineapple Energy (NASDAQ:PEGY) - Vimarsana News

Pineapple Energy Stock Soars: What's Going On? - Pineapple Energy (NASDAQ:PEGY)

Pineapple Energy shares are trading higher Tuesday. The company announced on Friday that its New York-based subsidiary SUNation signed a 1.95-megawatt project.

What's Going On With FuelCell Energy Stock? - FuelCell Energy (NASDAQ:FCEL) - Vimarsana News

What's Going On With FuelCell Energy Stock? - FuelCell Energy (NASDAQ:FCEL)

Earlier in May, President Joe Biden announced increased tariffs on a range of Chinese goods, including clean energy technologies, leading to a spike for FuelCell Energy shares. The stock initially gave back the gains, but has been climbing steadily since last week.

Check Out What Whales Are Doing With GOLD - Barrick Gold (NYSE:GOLD) - Vimarsana News

Check Out What Whales Are Doing With GOLD - Barrick Gold (NYSE:GOLD)

Merck's Multi-Billion Cancer Drug Keytruda Aces Late-Stage Breast Cancer Study (UPDATED) - Vimarsana News

Merck's Multi-Billion Cancer Drug Keytruda Aces Late-Stage Breast Cancer Study (UPDATED)

Editor’s Note: The title of the story is updated to correct the reference to ‘Breast’ cancer instead of ‘Lung’ cancer. Tuesday, Merck & Co Inc (NYSE:MRK) released topline data from hase 3 KEYNOTE-522 trial of Keytruda in high-risk early-stage triple-negative breast cancer (TNBC). The study evaluated Keytruda in combination with chemotherapy as a pre-operative (neoadjuvant) treatment and then continuing as a single agent after surgery (adjuvant). The study met its overall survival (OS) endpoint.

Source: yahoo.com